Approach to the older patient with cancer
© de la Cruz and Bruera; licensee BioMed Central Ltd. 2013
Received: 10 September 2013
Accepted: 16 September 2013
Published: 10 October 2013
The incidence of cancer increases with advanced age. And as the world populationages, clinicians will be faced with a growing number of older patients withcancer. The challenge that clinicians face involves carefully choosing the typeof therapeutic care plan that is most appropriate given a person’s levelof physical reserve, medical comorbidities, and psychosocial resources.Inclusion of assessment tools in clinical practice such as a comprehensivegeriatric assessment can assist clinicians in identifying patients who willbenefit from aggressive cancer care or palliative measures. The role ofpalliative care, especially in the frail older patient, is critical in improvingquality of life. Improvement in best care practices in older patients withcancer requires their inclusion in clinical trials.
KeywordsAdvance cancer Geriatric patient Palliative care Supportive care Symptom management
The incidence of cancer increases dramatically with age. Current statistics show thatabout 50% of cancers diagnosed in the United States occur in people over the age of65 and this is expected to rise to 70% by 2030. The incidence of cancer is reportedto be 12 to 36 times higher in patients 65 years or older compared with those aged25 to 44 years, and 2 to 3 times higher in individuals 45 to 64 years of age.Mortality is also higher in older patients, accounting for nearly 70% of cancerdeaths per year . The challenge for cancer specialists is to determine the optimumtreatment for elderly patients, a heterogeneous population in terms of comorbidity,disability, physical reserve, and other geriatric conditions. Best treatmentpractices for older patients with cancer are lacking, in part due to sub-optimal orexcessively toxic treatments and under-representation in clinical trials, resultingin poorer outcomes compared with younger patients. Issues that impact oncologic andsupportive care management unique to the geriatric population will be highlighted inthis article.
Aging is defined as a progressive loss of a person’s entropy and fractalorganization that limits the functional reserve of multiple organ systems and theability to withstand stress. Such changes bring about reduced life expectancy,increased susceptibility to disease and loss of personal independence. The processof aging varies from person to person. Some patients undergo successful aging, whererobust physical and cognitive abilities are maintained throughout life . There are those described as having frailty, which is characterized byweakness and decreased functional reserve [3, 4]. Physiologic age does not correspond to a person’s chronologic ageand is more clinically useful in medical decision-making. Determination ofphysiologic age is largely based on a comprehensive geriatric assessment (CGA). Thismulti-dimensional method incorporates functional status, comorbidities, cognition,nutrition, medications, and social support structures. It assists clinicians tobetter estimate life expectancy and functional reserve, which are relevant intreatment-related decisions. The use of the CGA also allows for identification offrailty and other unrecognized conditions that can influence management.
The older patient diagnosed with cancer can present with various other problems,making evaluation of treatment options for cancer more complex. Besidesconsideration of cancer-related factors, assessment of other aspects of apatient’s health status including social, functional, cognitive, economic andspiritual domains, is crucial in developing a treatment plan that is tailored toindividual needs. Since the mid-1990s, oncologists and geriatricians have sought tointegrate the use of CGA in the oncologic setting, hoping to assist clinicians informulating optimal therapeutic plans. Components of the CGA have been shown to notonly affect life expectancy and function but also tolerance to treatment and symptomburden. Box 1 lists questions that can affect therapeutic choices and measuretreatment efficacy and guide in planning care for the elderly .
Box 1 Questions to ask in deciding therapeutic care plan for the elderlycancer patient 
Is the patient going to die of cancer or with cancer?
Is the patient going to live long enough to suffer the consequences ofcancer?
Is the patient able to tolerate the treatment?
What are the long term consequences of cancer treatment in theelderly?
Will any treatment improve the quality of life?
What are the patient’s goals of care?
Is the social network of the patient adequate to support him/herduring the treatment?
Fried’s frailty criteria1 
Involuntary weight loss of 10 lbs or more in the last 6months
Fit (no abnormalities)
Reduced grip strength
Pre-frail (2 abnormalities or less)
Difficulty initiating movements
Frail (3 or more abnormalities)
Reduced walking speed
Frailty has rarely been measured in patients with cancer. Some evidence shows thatfrailty is present in younger patients with cancer, and can even be observed incancer survivors. This indicates that familiarity and understanding of the conceptof frailty is essential from the time of consideration of treatment to cure andsubsequent follow-ups. Most older adults with cancer will fall into the pre-frailand frail category, therefore it is important that supportive care measures be madeavailable to them. This requires access to palliative care services to managesymptoms that may arise from the burden of disease as well as the adverse effects ofcancer treatment. The interdisciplinary team that is central to the practice ofpalliative care is most useful in the geriatric patient. These patients will benefitfrom specialized care encompassing multiple domains for improved quality of life.Quantifying frailty can help reduce futile and burdensome interventions that are notexpected to improve symptoms or those that may worsen function and quality of life.Frailty assessment is therefore essential for the timely delivery of holisticpalliative care in geriatric patients with progressive and terminal disease .
With the aging of the population and the known association between cancer and olderage, inclusion of older geriatric patients in clinical trials has been advocated byseveral experts. The under-representation of this at-risk population has beenhighlighted by several authors . It has been proposed that exclusion in studies is related to reducedfunction, presence of comorbidities, concomitant medications, lack of access, andpoor social support. Proposals to improve participation of older adults includeclinical trials specifically designed for older adults with multiple comorbidities,trials with dosing regimens tailored for older patients, standardized use ofgeriatric tools, and alternative end points or outcomes [12–14]. Data from 2001 to 2010 showed that 24 drugs were approved by the US Foodand Drug Administration for cancer treatment and only 33% of patients that wereregistered in those trials were 65 years or older . This is a dismal representation given that 59% of patients with cancerduring the same time period were of this age group . The problem with non-inclusion is that evidence-based treatmentrecommendations are not always applicable to the older patient, particularly thosewho are vulnerable and frail. In addition, those included in the trials are notrepresentative of the majority of older adults with cancer. Designing protocolstailored to include older patients should be specially designed to avoidunder-representation. The CGA can be used as a tool that can classify patients fitto receive certain specific treatments other than using age and clinical judgment asthe sole basis for treatment decisions. Such clinical trials would be helpful inguiding appropriate patient selection, risk stratification, and toxicityevaluation.
The incidence of cancer rises with increasing age. Specialists who care for cancerpatients face the difficulty in identifying optimum treatment options for elderlypatients. The concept of frailty and the use of the CGA help guide treatmentdecisions, enabling clinicians to better identify the presence of comorbidities andgeriatric syndromes, and the level of physical reserve or disability. Incorporatingsupportive care measures early in these patients, particularly those who fall intothe pre-frail and frail categories of the frailty index, is crucial to successfulmanagement. Future cancer and palliative care research should be more inclusive ofthis population. Specially designed protocols for older adults are necessary toprovide more appropriate evidence-based approaches to cancer treatment ingeriatrics.
Comprehensive geriatric assessment.
The authors would like to acknowledge Ms Brittany Chenevert for her role inpolishing the manuscript.
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.PubMedView Article
- Fratiglioni L, von Strauss E, Winblad B: Epidemiology of aging with focus on physical and mental functionalability. Lakartidningen. 2001, 98: 552-558.PubMed
- Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G: Untangling the concepts of disability, frailty, and comorbidity: implicationsfor improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004, 59: 255-263. 10.1093/gerona/59.3.M255.PubMedView Article
- Campbell AJ, Buchner DM: Unstable disability and the fluctuations of frailty. Age Ageing. 1997, 26: 315-318. 10.1093/ageing/26.4.315.PubMedView Article
- Health and Public Policy Committee; American College ofPhysicians: Comprehensive functional assessment for elderly patients. Ann Intern Med. 1988, 109: 70-72.View Article
- Balducci L: New paradigms for treating elderly patients with cancer: the comprehensivegeriatric assessment and guidelines for supportive care. J Support Oncol. 2003, 1: 30-37.PubMed
- Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001, 56: M146-M156. 10.1093/gerona/56.3.M146.PubMedView Article
- Balducci L, Stanta G: Cancer in the frail patient. A coming epidemic. Hematol Oncol Clin North Am. 2000, 14: 235-250. 10.1016/S0889-8588(05)70286-0. xiPubMedView Article
- Walston J, Fried LP: Frailty and the older man. Med Clin North Am. 1999, 83: 1173-1194. 10.1016/S0025-7125(05)70157-7.PubMedView Article
- Koller K, Rockwood K: Frailty in older adults: implications for end-of-life care. Cleve Clin J Med. 2013, 80: 168-174. 10.3949/ccjm.80a.12100.PubMedView Article
- Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in clinical trials for cancer drugregistration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004, 22: 4626-4631. 10.1200/JCO.2004.02.175.PubMedView Article
- Hurria A: Geriatric assessment in oncology practice. J Am Geriatr Soc. 2009, 57: S246-S249.PubMedView Article
- Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA: Future of cancer incidence in the United States: burdens upon an aging,changing nation. J Clin Oncol. 2009, 27: 2758-2765. 10.1200/JCO.2008.20.8983.PubMedView Article
- Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ, Cancer and Leukemia Group B: Survey of oncologists’ perceptions of barriers to accrual of olderpatients with breast carcinoma to clinical trials. Cancer. 2002, 95: 989-996. 10.1002/cncr.10792.PubMedView Article
- Scher KS, Hurria A: Under-representation of older adults in cancer registration trials: knownproblem, little progress. J Clin Oncol. 2012, 30: 2036-2038. 10.1200/JCO.2012.41.6727.PubMedView Article
- Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS: Lung cancer in elderly patients: an analysis of the surveillance,epidemiology, and end results database. J Clin Oncol. 2007, 25: 5570-5577. 10.1200/JCO.2007.12.5435.PubMedView Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/11/218/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/2.0), whichpermits unrestricted use, distribution, and reproduction in any medium, provided theoriginal work is properly cited. The Creative Commons Public Domain Dedicationwaiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to thedata made available in this article, unless otherwise stated.